Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities: 2015-2025

Historic Total Non-Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $322.2 million.

  • Syndax Pharmaceuticals' Total Non-Current Liabilities rose 16108650.00% to $322.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.2 million, marking a year-over-year increase of 16108650.00%. This contributed to the annual value of $333.1 million for FY2024, which is 56556.97% up from last year.
  • Syndax Pharmaceuticals' Total Non-Current Liabilities amounted to $322.2 million in Q3 2025, which was down 1.09% from $325.7 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities peaked at $333.1 million during Q4 2024, and registered a low of $2,000 during Q3 2024.
  • In the last 3 years, Syndax Pharmaceuticals' Total Non-Current Liabilities had a median value of $864,000 in 2023 and averaged $119.6 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 99.77% in 2024, then spiked by 16,108,650.00% in 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $20.6 million in 2021, then slumped by 96.50% to $722,000 in 2022, then dropped by 18.56% to $588,000 in 2023, then surged by 56,556.97% to $333.1 million in 2024, then spiked by 16,108,650.00% to $322.2 million in 2025.
  • Its last three reported values are $322.2 million in Q3 2025, $325.7 million for Q2 2025, and $331.1 million during Q1 2025.